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Immunization alters body odor
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H I G H L I G H T S
• Biosensors discriminated between urines collected from donors receiving a rabies vaccine (RV) versus controls
• Biosensors discriminated between the urine odors of mice treated with lipopolysaccharide (LPS) from the urine of control mice
• LPS-trained biosensors could distinguish between the odors of LPS-treated mouse urine and RV-treated mouse urine.
• Discriminations by the biosensors were made on the basis of odor alone.
• Volatile metabolites arising from immunization may be products of an innate immune response.
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Infections have been shown to alter body odor. Because immune activation accompanies both infection and
immunization, we tested the hypothesis that classical immunization might similarly result in the alteration of
body odors detectable by trained biosensor mice. Using a Y-maze, we trained biosensor mice to distinguish
between urine odors from rabies-vaccinated (RV) and unvaccinated control mice. RV-trained mice generalized
this training to mice immunized with the equine West Nile virus (WNV) vaccine compared with urine of
corresponding controls. These results suggest that there are similarities between body odors of mice immunized
with these two vaccines. This conclusion was reinforced whenmice could not be trained to directly discriminate
between urine odors of RV- versusWNV-treatedmice. Next, we trained biosensor mice to discriminate the urine
odors of mice treated with lipopolysaccharide (LPS; a general elicitor of innate immunological responses) from
the urine of control mice. These LPS-trained biosensors could distinguish between the odors of LPS-treated
mouse urine and RV-treated mouse urine. Finally, biosensor mice trained to distinguish between the odors of
RV-treated mouse urine and control mouse urine did not generalize this training to discriminate between
the odors of LPS-treated mouse urine and control mouse urine. From these experiments, we conclude that:
(1) immunization alters urine odor in similar ways for RV andWNV immunizations; and (2) immune activation
with LPS also alters urine odor but in ways different from those of RV and WNV.
Published by Elsevier Inc.
1. Introduction
Chemical signals are the primary form of social communication for
many species [1–3]. Although most research has been devoted to
communication of social messages such as sex, age, and individual
identity, volatile odorants may also communicate information about
an animal's health status [4–6]. Odors associated with illness are often
avoided by members of the same species, presumably acting to reduce
the probability of disease spread [7]. Conversely, it might be adaptive
for the infective agent to induce chemosensory changes in the
host that increase both inter- and intraspecific interactions, thereby
increasing transmission rates. An example of attraction has been
demonstrated for interspecific interactions between human hosts and
an insect vector [8].
Themechanisms underlying changes in body odor caused by disease
are poorly understood and the specificity of odor changes to a specific
disease has rarely been explored. For some diseases the mechanism
underlying a body odor change is obvious and very non-specific. For
example, diseases that alter feeding and drinking behavior or gut
function are likely to alter odors associated with waste products such
as urine and feces in non-specific ways. A more interesting potential
pathway for diseases to alter body odor is via immune function —
which is known to be intimately related to body odor composition
[9–11]. Based on this reasoning, we hypothesized that vaccination
may induce a significant alteration of body odor.
To test this hypothesis, we first conducted experiments asking
whether immunization with rabies (RV) or West Nile virus (WNV)
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vaccines alters body odors as determined by trained sensor mice in Y-
maze odor training paradigm [12]. This behavioral assay is well-
equipped to identify differences among various stimuli on the basis of
odor. The Y-maze has successfully been used to demonstrate that ro-
dents can discriminate between many different sources of odor varia-
tion, including: fetal odortype [13,14], disease [12,15], age [16], and
diet [17]. We used urine as a representative source of body odor in
these experiments because it is a potent source of mouse body odors
[12,18].
Finding that urine odors were altered by treatment with the vac-
cines, we next examined whether odor changes are also elicited from
exposure to lipopolysaccharide (LPS), a component of bacterial cell
walls. Treatment with LPS induces a robust pro-inflammatory cytokine
response [19] and previous experiments have indicated that body
odors from LPS-treated animals elicit aversive behavioral responses
from conspecifics [20]. The Y-maze odor training paradigm was used
to evaluate similarities in body odor alterations produced by these dif-
ferent immunogens.
2. Materials and methods
2.1. Subjects
Inbred C57BL/6micewere used as both biosensors and urine donors
receiving treatments. Three biosensor panels (a unique panel for
each experiment) each consisted of 5–7 individuals of mixed sex
ranging in age from 6 to 14 months (Table 1). Urine donors were
males 7–10 weeks of age at the time of treatment. The number of
donors in each treatment group depended on the number of samples
needed for bioassay trials (Table 1). Treated urinedonorswere provided
ad libitum access towater and pelleted rations. Biosensorswere provid-
ed ad libitum feed (Teklad Rodent Diet 8604; Harlan, Madison,WI), but
were restricted fromwater for 23 h daily. Procedures involving animals
were approved by the Institutional Animal Care and Use Committees of
Monell (#1123) and the United States Department of Agriculture, Ani-
mal and Plant Health Inspection Service, Wildlife Services, National
Wildlife Research Center (QA-2021).
2.2. Treatments
The inactivated rabies vaccine RabVac-3® (RV; Fort Dodge Animal
Health, Fort Dodge, IA, USA) was diluted (1:15) in 0.01 M sterile
phosphate-buffered saline (PBS) for i.p. delivery of 300 μL. The live,
attenuated West Nile virus (WNV) vaccine, PreveNile® (Intervet, Inc.,
Millsoboro, DE, USA) was prepared by dissolving 15 mg of the vaccine
in 100 mL PBS for i.p. delivery of 200 μL. Vaccine dilution rates (based
on relative mass ratios among species of intended vaccine use) resulted
in ~50× reduction of RV dose as indicated for pets and ~1500× reduc-
tion of WNV vaccine dose as recommended for horses. The lipopolysac-
charide (LPS) solution was prepared in PBS at a concentration of
0.20 mg/mL for i.p. delivery of 300 μL (60 μg per mouse or ~2 mg/Kg).
LPS doses exceeding 12 mg/Kg (~400 μg per mouse) have been used
in C57BL/6 inflammation models [21]. Donors in control groups
received matching volume i.p. injections of PBS solution. Different
groups of donors were employed for each of the three experiments
(Table 1).
2.3. Urine stimuli
Urine collection from treated donors commenced on day four post-
treatment by application of abdominal pressure as previously described
[22]. Urine was collected daily for several weeks. Expressed urine from
each subject was collected in a vial and frozen until used for behavioral
assays. To attain the necessary volumes for bioassay, samples collected
from the same individual on multiple collection days were often com-
bined. Unless otherwise specified, training trials were conducted with
urine collected 4–13 days post-treatment with RV, WNV, or LPS.
2.4. Apparatus
A Y-maze was used for biosensor training and testing as previously
described [12]. Air was conducted through two odor chambers, contain-
ing urine (0.5 mL) exposed in 35 mm Petri dishes (11 mL) to the two
arms of the maze (Table 1). Samples were randomly assigned to the
left or right odor boxes of the Y-maze. Gates were manually raised
and lowered in timed sequence to permit the training or testing of
each mouse in a session of up to 48 consecutive trials. The reward for
a correct responsewas a drop of water (themouse having been restrict-
ed of water for 23 h).
2.5. Experiment 1
Experiment 1 was conducted to determine if the administration of
RV altered body odor and to investigate if this learned response was
generalized to a different vaccine treatment. For Experiment 1a, daily
training sessions consisted of pair-wise offerings of urine from individ-
ual control and RV donors and the reward was always associated with
RV-urine. Training continued daily until each biosensor achieved great-
er than 80% concordance (correct response to stimulus associated with
reward). Throughout training, unrewarded trials were interspersed (on
average 25% of the time) among rewarded trials.
Following training, testing sessions consisted of rewarded training
trials with interspersed unrewarded training trials (extinction) and un-
rewarded generalization trials (total of four per session). Experiment 1a
consisted of three different generalization experiments (Table 1). The
first, andmost important, generalizations constituted the validation ex-
periment designed to demonstrate that the trained response was relat-
ed to the vaccine treatment. Validation trials employed stimuli from the
same treatment groups as used in training sessions with the important
exception that urine samples were collected from novel individual
mouse donors (not used during training). Five sessionswere completed
in the validation experiment, resulting in 78 total validation trials
among the seven biosensors. Additional generalization tests were
paired comparisons of WNV-urine versus control urine (69 trials in
four sessions) and WNV-urine versus RV-urine (59 trials in six
sessions).
Experiment 1b was conducted when it was concluded that treat-
mentwith the two vaccines resulted in similar odor alterations. Training
sessions were initiated with the Experiment 1a biosensor panel to
Table 1
Overview of trials conducted in a Y-maze with number of donors by treatment and urine
collection days (post-treatment). Rabies (RV) = treatment with RabVac-3® vaccine;
West Nile virus (WNV) = treatment with PreveNile® West Nile virus vaccine; LPS =
treatment with lipopolysaccharide; and control = treatment with phosphate-buffered
saline.
Experiment Traininga Generalizationb Donors
1a RV vs. control (7)c RV vs. control (validation) 70 RV
WNV vs. control 30 control
WNV vs. RV 16 WNV
1b RV vs. WNV (7)d None
2a LPS vs. control (3) LPS vs. control (validation) 40 LPS
LPS vs. control (3) LPS vs. control (validation) 20 control
10 RV
2b LPS vs. control (7)e LPS vs. RV
3 RV vs. control (5) RV vs. control (validation) 21 RV
LPS vs. control 17 control
a Odors associated with treatments in bold were the rewarded choice in training trials.
b Identities of stimuli were blind to the operator during generalization trials and were
unrewarded.
c Number of subjects in the biosensor panel is indicated in parentheses.
d Experiment 1b donors are the same as Experiment 1a.
e Experiment 2b donors are derived from Experiment 2a.
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directly discriminate RV-urine and WNV-urine. The water reward was
associated with urine odors from RV vaccinated mice. Because biosen-
sors showed no evidence of discrimination between urines collected
from donors receiving the two vaccines, no generalization trials were
run in Experiment 1b.
2.6. Experiment 2
Investigation of LPS-induced odor change was conducted in two
phases to determine if LPS-trained mice could discriminate LPS- and
RV-urines in a paired comparison. In Experiment 2a, mice were trained
to discriminate between urine odor pairs from control and LPS-treated
donors collected 4–8 days post-treatment. Three biosensor mice were
rewarded for choosing the maze arm associated with LPS urine odor
and three were rewarded for association with control urine odor
(Table 1). There were six validation sessions (control versus LPS-urine
collected days 4–8 from novel donors) resulting in 69 trials. To facilitate
generalization testing with RV, a new panel of trained mice in Experi-
ment 2b consisted of the three biosensors that had been rewarded for
selection of LPS during Experiment 2a as well as four naive subjects.
Training was similar to Experiment 2a except that all mice were
rewarded for selection of odor associated with LPS treatment. One bio-
sensor died during Experiment 2b. The single generalization experi-
ment (LPS-urine versus RV-urine collected on days 7 and 8) consisted
of six sessions resulting in 46 trials.
2.7. Experiment 3
The final experiment was conducted to determine if mice trained to
recognize urine fromRV-mice generalized the learned response to urine
from LPS-mice. Employing a new biosensor panel, training was con-
ducted identically to Experiment 1a (paired comparison of RV-urine
and control urine with reward associated with RV-urine). There were
9 validation sessions (control versus RV-urine collected 4–22 days
post-treatment from novel donors) resulting in 97 trials. The other
generalization experiment (pairing control versus LPS-urine collected
4–14 days post-treatment) resulted in 56 trials in 3 sessions.
2.8. Data analysis
Correct responses for individual biosensors during training were
subjected to chi-square tests of independence.When training responses
did not differ among individuals, cumulative responses of the full panel
were calculated for training and subsequent generalization trials.
Success rates (number of correct trials divided by total trials) for specific
generalization trials were subjected to statistical tests of binomial
proportion using the continuity correction for low incidence events
[23]. No comparisons were made among generalization trial types. For
Experiment 2a, an additional test (chi-square test of independence)
was conducted to determine if training responses differed according
to the stimulus associated with the water reward (LPS or control).
3. Results
Following treatment, subjects receiving LPS treatment demonstrat-
ed visible indicators of sickness — i.e., lethargy and dehydration.
Reduced urinary output, while not explicitly measured, was evident
during urine collection for up to 5 or 6 days following LPS administra-
tion. No similar effects were observed among subjects treated with
the vaccines or control.
3.1. Experiment 1
Trained mice could discriminate RV-urine from control urine by
smell. Overall, biosensor concordance was 90% in rewarded training
trials in Experiment 1a. The proportion of correct responses did not
differ among individual biosensors during training (p= 0.10). In vali-
dation trials, biosensors correctly chose the maze arm associated with
urine of novel RV-treated donors in 51 out of 78 (65%) unrewarded tri-
als versus control urines (p = 0.0046; Fig. 1). In a second set of
generalization trials, biosensors trained to respond to RV vaccine-
treated urine selected the maze arm associated with the urine of West
Nile virus (WNV) vaccine-treated donors in 49 out of 69 (71%) unre-
warded trials versus controls (p = 0.0004) suggesting that RV and
WNV treatments result in similar volatile odor profiles. Biosensors
offered RV and WNV urines in direct comparisons did not discriminate
between the two different immunization types 36 out of 68 times
(53%; p= 0.36; Fig. 1).
Training trials employing direct pairing of RV-urine andWNV-urine
in Experiment 1b were not successful. No progress toward concordance
was evident after six consecutive training sessions. Whereas the novel
biosensor panel trained in Experiment 1a correctly identified RV-urine
(paired with control urine) in 62% of trials (p b 0.0001 for H0 = 50%)
after six sessions; the Experiment 1b panel identified RV-urine in only
44% of the trials when paired WNV-urine donors in rewarded trials. As
a result of this performance, the experiment was terminated.
3.2. Experiment 2
LPS-trained mice discriminated between LPS- and control mice
as well as between LPS-urine and RV-urine in paired comparisons.
The new biosensor panel discriminated LPS and control urine in
rewarded training trials (82% concordance). Response rates did not
differ among individuals during training (p = 0.15) and were not
impacted bywhich urine was reinforced (LPS or control) in Experiment
2a (p =0.20). In validation trials, biosensors selected the maze arm
associated with LPS urine when paired with control urine 47 out of 69
times (68%; p= 0.0019; Fig. 2). In generalization trials with RV-urine,
discrimination was observed when LPS-urine was compared with RV-
urine 36 out of 46 times (78%; p= 0.00011).
3.3. Experiment 3
RV-trained mice did not generalize the response to LPS-urine. Five
new biosensors were successfully trained to discriminate urine of RV
vaccine-treated donors versus controls (87% concordance). The pro-
portion of correct responses did not differ among individual biosensors
during training (p = 0.58). In validation trials with urine of novel do-
nors, biosensors selected the maze arm associated with urine of RV
Fig. 1. Biosensor results from Experiment 1a. Mean responses are provided with 95%
confidence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine; West Nile
virus = treatment with PreveNile® vaccine; and control = treatment with phosphate-
buffered saline.
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vaccinated donors in 65 out of 97 unrewarded trials (p = 0.0006;
Fig. 3). However, RV-trained mice did not discriminate between urines
of LPS-treated and control donors in generalization trials (24 out of
56; p=0.18; Fig. 3). These results suggest that volatile cues associated
with LPS treatment were different from the volatiles used by trained
biosensors to identify RV-urine.
4. Discussion
Mice were successfully trained to discriminate urines from RV-
treated and control mice (Figs. 1 and 3) as well as urines from LPS-
treated and control mice (Fig. 2). The training response was validated
with generalization trials employing urine samples from donors that
were unfamiliar to the trainedmice. The purpose of these validation tri-
als was to exclude the possibility that individual cues, rather than treat-
ment effects, could have been used to characterize urine samples used
during training. Information regarding the identity of samples used in
these generalization trials could be withheld from the maze operator
(thereby making her blind to the expected results) which was possible
because the generalization trials were unrewarded. Validation results
demonstrated that biosensor discrimination was made on the basis of
odors related to LPS or RV treatments, not cues learned about the
urine donors or the training paradigm.
In Experiment 1a, RV-trained biosensors generalized their response
to RV-urine by discriminating urines fromWNV-treated and control do-
nors. However, RV-trained biosensors did not discriminate RV- and
WNV-urines when presented in unrewarded head to head comparisons
(Fig. 1); neither was discrimination observed after six training sessions
with RV- and WNV-urines in Experiment 1b. Although we cannot be
certain that training with RV- and WNV-urines would not have been
successful withmany additional trials, these data (along with consider-
able past experience with the Y-maze training paradigm) led us to
conclude that odor changes induced by these two vaccines were per-
ceptibly very similar.
To our knowledge, these are the first data to demonstrate that im-
mune activation causes the expression of a distinctive odor. Because
the design of the Y-maze ensures that biosensors cannot make contact
with the odor stimuli, it is certain that the cues responsible for biosensor
discrimination are volatile compounds. Yet, themechanisms underlying
these odor changes remain in question. Volatile metabolites may arise
at any point in the complex processes of innate or adaptive immunity.
Major histocompatibility complex (MHC) variation has been identified
as a source of odor differences [22]. However, aspects of the current
study may exclude adaptive immunity as a source of metabolites indic-
ative of vaccination. First, discrimination of vaccination status is appar-
ent in as few as four days, presumably too early to implicate adaptive
immunitywhich occurs over severalweeks. For example, peak antibody
production in humans has been observed between 14 and 28 days for
RV [24] and WNV vaccines [25]. Second, inactivated vaccines (e.g., RV)
do not participate in the cellular MHC class I pathway analogous to
live vaccines such as WNV [26]. The perceptual similarities between
RV and WNV-produced odors suggest that innate immunity processes
may be responsible for the volatile metabolites [27]. Innate immunity
triggers inflammation and initiates adaptive immunity via the comple-
ment system within hours of antigen presentation.
As afirst step toward examining thepossible role of an innate immu-
nity activation pathway to odor change, we examined odor changes
elicited by exposure to the potent immune activator, LPS, the prototyp-
ical bacterial endotoxin [28]. This was chosen, in part, because LPS has
been used to induce “sickness-related odors” in mice [29]. In particular,
rats exhibited avoidance behaviors of soiled bedding material collected
from conspecifics four hours after receiving 100 μg/Kg doses of LPS;
which could be blocked by the administration of anti-inflammatory cy-
tokine IL-10 [29]. Validation trials in Experiment 2a indicated not only
that the biosensor response was related to treatment, but also that dis-
crimination was possible regardless of which choice (LPS- or control
urine)was associatedwith the reward. Because Experiment 2b required
the biosensors to generalize their response to LPS-urine odors, a new
panel consisting of individuals reinforced to LPS-urine odor was assem-
bled. Biosensor discrimination of LPS urine and RV urine demonstrated
that LPS and RV administration produced distinct alterations in volatile
urine metabolites (Fig. 2).
These results also suggest that the odor alterations resulting from
treatment with LPS or RV are not merely quantitatively different. If the
salient odor cues of RV-urine were quantitatively greater than the
odors resulting from LPS treatment, biosensorswould have likely gener-
alized the control response to the weaker LPS signal. Rather, theymain-
tained the response to LPS-related odors and discriminated LPS- and
RV-urines. Likewise, biosensors would have discriminated LPS-urine
and control-urine in Experiment 3 if the odor cues of LPS-urine were
merely quantitatively greater than RV-urine odors.
A new panel was directly trainedwith LPS urine and control urine in
Experiment 3. Biosensors trained to discriminate RV-urine and control
urine did not generalize this response to LPS urine in Experiment 3
(Fig. 3), further indicating that these two activators of the immune
Fig. 2. Biosensor results from Experiment 2. Mean responses are provided with 95%
confidence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine;
lipopolysaccharide (LPS) = treatment with LPS solution in buffered saline; and control
= treatment with phosphate-buffered saline.
Fig. 3. Biosensor results from Experiment 3. Mean responses are provided with 95%
confidence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine;
lipopolysaccharide (LPS) = treatment with LPS solution in buffered saline; and control
= treatment with phosphate-buffered saline.
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system induced different alterations of urine odor. Although outward
indicators of acute inflammation (e.g., lethargy, dehydration) were
evident for subjects treatedwith approximately 2 mg/Kg LPS in the cur-
rent study, it is unlikely that inflammation per sewas responsible for the
differences in RV- and LPS-related odors. Peak inflammatory cytokine
levels in mice administered with 3 mg/Kg LPS are commonly observed
approximately four hours after treatment and return to baseline levels
after 24 h [21]. Furthermore, RV and control odorswere readily discrim-
inated by the biosensors (Fig. 1) despite the fact that inactivated viruses
(such as RV) lack the capacity to elicit potent inflammatory responses
[30].
Volatile cues present in urinemany days after treatment with LPS or
vaccine likely represent the “memory” of an innate immunity process
that differs between these immunogens. Interaction with Toll-like
receptors (TLRs) is one example of howdifferent classes of immunogens
may differ in innate immunity. Recognition by the innate immune sys-
tem is accomplished by a number of pattern recognition receptors. For
example, cell surface recognition of LPS is accomplished by TLR4 [19].
Conversely, a variety of TLRs, RIG-I-like receptors (RLRs), and NOD-
like receptors (NLRs) are responsible for cytoplasmic and endosomal
recognition of viruses [31]. Discrimination between LPS- and RV-urine
odors (Fig. 2) and inability to discriminate between odors resulting
from the two vaccines (Fig. 1) are consistent with the concept that im-
munogens interacting with similar pattern recognition receptors elicit
similar volatile cues.
Following the detection of an immunogen, a number of innate im-
munity processes are initiated: antimicrobial enzymes and peptides
are released, inflammatory processes may be triggered, and attachment
of antigens to phagocytes is promoted. Among the biochemicals re-
leased to achieve these tasks are lipases, cytokines, and complement
protein complexes. The volatile cues detectable by trained mice may
be influenced by any or all of these cellular events. Specifically, differ-
ences between LPS and the vaccines may be related to the complement
system. Complement proteins participate in innate immunity and initi-
ate adaptive immunity. Because complement participates in the humor-
al response via interactions with immunoglobulins [19], it might be
expected that the complement protein cascade responding to a bacteri-
um (e.g., LPS) would differ from a viral response (e.g., RV orWNV). The
finding that the volatile signatures of RV andWNV vaccines are similar,
although different from LPS, may be related to this aspect of innate
immunity.
Metabolic inputs to innate immunity may be another source of
the volatiles used by the biosensors to discriminate treatments.
Using LPS and keyhole limpet hemocyanin (KLH; a very large immu-
nogenic protein often employed in vaccines) treatments in mice, a
tradeoff between innate immunity and maximal metabolic rate was
observed — but no such cost was evident for adaptive immunity
[32]. Differences in volatiles arising from LPS treatment as compared
with the vaccines may reflect differences in the costs of innate re-
sponses to these immunogens. Therefore, anabolic and/or catabolic
pathways required for meeting the energy requirements of innate
immunity may themselves be the source of the volatile cues. For ex-
ample, prolonged fasting produces markers indicative of amino acid
catabolism in humans, including volatile metabolites [33]. Non-
volatile metabolites of folate catabolism persist up to eleven days
in rats following administration of radio-labeled folic acid [34].
Liver functions, such as cytochrome P-450 metabolism, may also be
impacted by inflammation. Reduced P-450 metabolism was ob-
served in mice 24 h after i.p. treatment with LPS [35]. In summary,
volatile cues of immunization detectable by trained mice may result
directly from immunogen recognition or response pathways; or in-
directly via persistent metabolites associated with the metabolic
cost of innate immunity. Perhaps the mechanism could be further
elucidated in a series of bioassays employing urine collected from re-
ceptor knock-out transgenic mouse strains and/or donors treated di-
rectly with cytokines.
An important question raised by these studies is the potential role
that vaccination-induced odor changes may have in the context of nor-
mal social behavior of the species. Generally speaking, disease-based
odors are avoided by conspecifics [36–38] which probably functions to
limit the transmission of disease. If some or all of the odor changes in-
dicative of disease are consequences of immune activation, one would
predict that vaccination-induced odors such as those we have studied
here may also be avoided. This hypothesis is now under investigation.
If this is so, large-scale immunization projects (e.g., to limit spread of ra-
bies in raccoons [39]) could have unintended consequences for social
and reproductive behaviors.
In conclusion,we have demonstrated that volatilemetabolites indic-
ative of some aspect of innate immune activation are present in the
urine several days following i.p. administration of two different vaccines
or LPS. Odor differences induced by the two vaccines (RV and WNV)
were apparently imperceptible. However, it is still an open question as
to whether other vaccination-induced odors can be differentiated. This
is significant because themore specific the odor change, themore useful
these odors could be for monitoring specific immunization status. Also,
further research is necessary to identify the metabolic pathway(s) re-
sponsible for these odor and odorant changes, their underlying chemi-
cal bases, their potential role in modifying social behavior, and their
diagnostic capabilities.
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